New Zealand markets closed

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.6591-0.0780 (-10.58%)
At close: 04:00PM EDT
0.6600 +0.00 (+0.14%)
After hours: 06:52PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 52.16M
Enterprise value 12.47M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.98
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.21

Trading information

Stock price history

Beta (5Y monthly) 1.02
52-week change 3-72.77%
S&P500 52-week change 3-10.33%
52-week high 32.4500
52-week low 30.4900
50-day moving average 30.9580
200-day moving average 30.8786

Share statistics

Avg vol (3-month) 3216.42k
Avg vol (10-day) 3203.45k
Shares outstanding 571.46M
Implied shares outstanding 6N/A
Float 841.32M
% held by insiders 139.16%
% held by institutions 14.58%
Shares short (14 Mar 2023) 41.41M
Short ratio (14 Mar 2023) 48.69
Short % of float (14 Mar 2023) 43.25%
Short % of shares outstanding (14 Mar 2023) 41.98%
Shares short (prior month 14 Feb 2023) 41.14M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-155.95%
Return on equity (ttm)-474.37%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -87.42M
Net income avi to common (ttm)-315.74M
Diluted EPS (ttm)-1.8300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)18.25M
Total cash per share (mrq)0.27
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)3.08
Book value per share (mrq)0.25

Cash flow statement

Operating cash flow (ttm)-42.72M
Levered free cash flow (ttm)-78.63M